US Army Purchases

Deltex Medical Group PLC
20 September 2005



20 September 2005



            Deltex Medical Group plc ('Deltex Medical' / 'Company')

   US Army hospital purchases four CardioQTM monitors for routine use in the
                   management of surgical and trauma patients



Deltex Medical Group plc, the AIM listed haemodynamic monitoring company, today
announces that it has sold four CardioQ monitors and an initial stock of
disposable oesophageal probes to the William Beaumont Army Medical Center in El
Paso, Texas.  The monitors are intended for use in medical and surgical patients
in the intensive care unit and those patients undergoing elective or emergency
surgery in the operating room.  Physicians at the hospital are also working to
make the CardioQ an integral part of patient care in a wider range of clinical
applications, including trauma surgery and neurosurgery.


The William Beaumont Army Medical Center provides care for active service
personnel and their families and also provides infrastructure and personnel for
battlefield support as required.


Andy Hill, Deltex Medical's Chief Executive, commented:


'This sale is the result of a recent successful evaluation of the CardioQ in
patients at the William Beaumont Army Medical Center in medical intensive care
and in surgery.  We are looking forward to working with the anesthesiologists,
intensivists, surgeons, and managers at the hospital as they continue to
implement CardioQ-based haemodynamic monitoring as a standard of care.'



For further information, please contact:-


Deltex Medical Group plc                                          01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director


Financial Dynamics                                                0207 831 3113
David Yates / John Gilbert



Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.



There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-



  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works



  • proved that the CardioQ works in a wide range of surgical procedures



  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange